Our results indicate that the GLI2/ARHGEF16/CKAP5 axis promotes glioma progression by enhancing tumor cell migration and proliferation and could therefore serve as a therapeutic target for glioma treatment. Here, ARHGEF16 is linked to central nervous system cancer.